Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions

Full Text:

Abstract

The aim is to analyze the medical records of patients with malignant lymphoproliferative diseases (LPD) in the Russian Federation in 2016- 2017. Materials and methods. Treating physicians in 75 regions of the Russian Federation were asked to fill the survey questionnaire containing 9 types of malignant LPDs (according to the ICD-10 classification). The questions covered the epidemiology of LPD (prevalence, resistant forms, relapses and mortality), the existence of specialized institutions and beds, the costs of medical care in patients with malignant LPD, and the financial support of pharmacotherapy in these patients during their hospital stay. Results. We found that the most common malignant LPD in 2016-2017 was Hodgkin’s lymphoma (73.5 and 73.4%, respectively). The prevalence of resistant forms and recurrences of malignant LPD over this period accounted for 6.8% of the total patient population. In 2017, the number of patients who died was 7.5% less than that in 2016. There are 815 and 1,763 specialized institutions of the oncology and hematology profiles that provide medical care to children and adult patients, respectively. Among the malignant LPDs, the highest costs of drug therapy in 2016 pertained to lymphosarcoma, and in 2017 – to Hodgkin’s lymphoma. In the system of compulsory health insurance (OMC), the largest spending for both adult and pediatric patients in 2016 and 2017 was accounted for Hodgkin’s lymphoma; a similar result was obtained for the cost of therapy based on high-tech medical care. Conclusion. In 2017, the total number of patients with malignant LPD in the Russian Federation increased by 2.65% as compared to 2016, while the proportion of primary LPD decreased by 1.2%. In 2017, the total costs of drug supply in patients with malignant LPD in the RF increased by 55.35% as compared with 2016.

Keywords

About the Authors

Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Research Financial Institution of the Ministry of Finance of the Russian Federation;
Russian Presidential Academy of National Economy and Public Administration Russian Federation

Georgii R. Khachatryan – Acting Director, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Researcher at the Laboratory for HTA, Institute of Applied Economic Research of the Presidential Academy; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute;

Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Sechenov First Moscow State Medical University Russian Federation

Tatyana S. Teptsova – Leading Specialist, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Post-graduate Student at the Department of Pharmacology, Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation;

Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Sechenov First Moscow State Medical University Russian Federation

Valeriya A. Lemeshko – Leading Specialist, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Post-graduate Student at the Department of Pharmacology, Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation;

Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Research Financial Institution of the Ministry of Finance of the Russian Federation;
Sechenov First Moscow State Medical University Russian Federation

Nuriya Z. Musina – PhD, Associate Professor at the Department of Pharmacology, Faculty of Pharmacy, Sechenov First Moscow State Medical University; Head of the Development and Communications Department, Center of Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation, Senior Researcher at the Center for Healthcare Funding, Financial Research Institute;

15. Ignatyeva V. I., Avksentyeva M. V. Analysis of the methodological features of research on the socio-economic burden of diseases in the Russian Federation as part of the development of a standard methodology for analyzing the cost of the disease in order to use it in the evaluation of health technologies. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern pharmacoeconomics and pharmacoepidemiology. 2014; 7 (3): 3-11 (in Russian).

G. R. Hachatryan
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Research Financial Institution of the Ministry of Finance of the Russian Federation;
Russian Presidential Academy of National Economy and Public Administration Russian Federation

Georgii R. Khachatryan – Acting Director, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Researcher at the Laboratory for HTA, Institute of Applied Economic Research of the Presidential Academy; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute;

10-5 Khokhlovskii pereulok, Moscow 109028;

3-2 Nastasyinsky pereulok, Moscow 127006;

82 Vernadskogo prospect, Moscow 119571

T. S. Teptsova
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Sechenov First Moscow State Medical University Russian Federation

Tatyana S. Teptsova – Leading Specialist, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Post-graduate Student at the Department of Pharmacology, Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation;

10-5 Khokhlovskii pereulok, Moscow 109028;

8-2 Trubetskaya Str., Moscow 119048

V. A. Lemeshko
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Sechenov First Moscow State Medical University Russian Federation

Valeriya A. Lemeshko – Leading Specialist, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Post-graduate Student at the Department of Pharmacology, Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation;

10-5 Khokhlovskii pereulok, Moscow 109028;

8-2 Trubetskaya Str., Moscow 119048

N. Z. Musina
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation;
Research Financial Institution of the Ministry of Finance of the Russian Federation;
Sechenov First Moscow State Medical University Russian Federation

Nuriya Z. Musina – PhD, Associate Professor at the Department of Pharmacology, Faculty of Pharmacy, Sechenov First Moscow State Medical University; Head of the Development and Communications Department, Center of Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation, Senior Researcher at the Center for Healthcare Funding, Financial Research Institute;

Cookies policy

The web-site of this journal uses cookies to optimize its performance and design as well as special service to collect and analyze data about pages visitors. By continuing to browse this web-site you agree to use cookies and the above service.